Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
I think nolupus just likes a bit of attention. On the subject of seeing the other side Dallo - what’s the situation with the patents at the minute? Have they got a plan to extend? From memory, US expires 2026, Europe has a bit longer - something like 2032 - both from memory and happy to be corrected.
“Imm invested £2.25 million into Incanthera and they are still on a papier loss on that investment AT this Time…” But so what, nolupus? The thing that matters is whether the value of the incanthera asset was priced in to the valuation of Imm stock. The point that it trades at a paper loss is rather irrelevany if that loss was already priced in to Imm stock… You say you can see the potential here - why not tell us about that?
The obvious point is - if/when we get details of phase 3 and news of a partnership - the shares will no longer be at 2p anymore. They will likely be at some multiple of it. The whole point is to assess the risk/return while in a state of uncertainty, not wait for the uncertainty to be removed and the shares respond. I’m sure some people have lost their shirts in immupharma - but often forgotten - many made excellent returns by buying during the scepticism at 20p, early on during the last phase 3 trial. In fact, by the time the result was announced in 2018, , I had already paid off my original investment by selling shares at a multiple of what I had bought them for - and ran a free position. Happy to be corrected, Ibut I don’t recall the current crop of sceptics among those who ran similar positions..
my largest recovery positions are synthomer, gms and renold. the latter two have really motored over the last 12 months but are well leveraged into recovery. more speculative - speedy hire - rock bottom valuation but quite an opaque near term outlook - could spring up or down short term but hopefully more comfortable mid/long term. highly speculative - carclo and immupharma - proper **** or bust names. buyer beware but potential to multiply many fold if recovery achieved. i also have some asos - hopefully u.k. consumer beyond the worst. happy hunting. imo dyor
Absolutely Yorkshire - I am not suggesting this returns to 180p. But I am suggesting that a similar multiplication off the lows is entirely possible - into the 15-20p range. They just need a small bit of success to start the ball rolling.
The key thing here is this will be a phase 3 - pretty unique for a company of this size. It will take only a very small inflow from an outsourcing deal to bring that point into focus. No more dilution - just a phase 3 in a blockbuster indication. This is what the successful investors recognised prior to the last phase 3 when the shares were 20p or thereabouts , and consequently multiplied above 180p. They need to do very little to kickstart that engine all over again. IMO. DYOR
GMHK - well done holding onto your shares and I agree - there are few large liquid shares with equivalent recovery potential to SYNT. In previous posts I’ve estimated that at £7+ within 3 years - which I think is an attractive return and sensible horizon. Hopefully we get there a lot sooner! One of the interesting things from the last results is that over 50% of revenue and an even greater proportion of EBITDA is currently specialty chem - nice premium quality cash flow while we wait for broader recovery… ATB
it is the market that is making you and your trades look ridiculous, joseywales. don’t shoot the messenger. the latest is that you sold at 140p, were unconvinced at 155p, sold at 190p and again at 215p. shares now 235p+. this is after reporting buys between 300-500p. you are evidently no great trader, pal… jeez, even a simple buy and hold would massively outperformed that ****e, especially if buying at prograsivwly lower prices. and sorry to hear about your ailment - i’m guessing it is oral thrush? perhaps if you stop talking bwollox and aggrandising yourself then it will go away. atb
Hi walkietalkie,
So maybe JW does something entirely different to what he/she posts here. Perhaps what he/she says and what he/she does are entirely different things.
But what possible use is that to anyone, or at least, to anyone with a brain cell?
Regarding buying low and selling high - that’s not a strategy, pal. It’s just a truism. It’s called “making a profit” and is sort of what everyone is trying to do.
For the record, having reported buys at 500p, 400p, “slam dunk buys” at 300p, then sells at 140p, 190p and 215p, there is nothing in JW’s posts that suggest a profit has been made. But hey, sounds like your kind of investor :) ATB
Well I very rarely post on this board, nolupus. But I do think the purpose of these boards is for fun as well as to gather information. I understand why people come here and talk enthusiastically about their investments - that seems human. Buyer beware and only bet what you can afford, of course… But I have no idea why people come here and repeatedly and blandly undermine every announcement and every positive suggestion. That behaviour is just weird. Hope that explains. ATB
These options are reasonable compensation given that management are likely not currently paying themselves much. And that is why they are able to commit to no near term dilution. Like him or not, TM has kept IMM afloat and done a good job developing a relationship with Avion which gives them a reasonable chance of building something from here. He deserves to be remunerated for that, these sizeable option will hopefully keep him interested in the possible absence of a salary. ATB
Lambo has gone quiet. Hopefully no one listened to him and sold near the bottom… Just a thought - is Flash just Lambo using a different username… Same highly unusual need to grab attention by knocking a stock in which he appears to have little interest. I say unusual because most people have better things to do with their time :)
The expert trader JW was selling at 140p, not convinced at 155p, selling at 190p, selling at 215p… surely at some point he/she has to get something right. Of course I wouldn’t mention it, but he/she was rather adamant about his/her trading prowess … :)
Yes. Has been a great recovery. Our self professed “expert traders” have had a difficult time - it all started going wrong for them when they started posting their trades here first, rather than making them up after the event. ATB
This is the most interesting part for me. The EBITDA line may be depressed currently but heavily weighted to higher quality business. Onwards and upwards hopefully! ? ?We have increased the speciality weighting of our portfolio to c.55% of revenue, and a higher proportion of EBITDA currently.?